Cargando…
Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
Although the albumin-to-globulin ratio (AGR) is a promising biomarker, no study has investigated its prognostic significance for advanced urothelial carcinoma (UC). This study conformed to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria. We retrospectively reviewe...
Autores principales: | Taguchi, Satoru, Kawai, Taketo, Nakagawa, Tohru, Nakamura, Yu, Kamei, Jun, Obinata, Daisuke, Yamaguchi, Kenya, Kaneko, Tomoyuki, Kakutani, Shigenori, Tokunaga, Mayuko, Uemura, Yukari, Sato, Yusuke, Fujimura, Tetsuya, Fukuhara, Hiroshi, Enomoto, Yutaka, Nishimatsu, Hiroaki, Takahashi, Satoru, Kume, Haruki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329063/ https://www.ncbi.nlm.nih.gov/pubmed/34341416 http://dx.doi.org/10.1038/s41598-021-95061-z |
Ejemplares similares
-
Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
por: Kawai, Taketo, et al.
Publicado: (2022) -
Improved survival in real‐world patients with advanced urothelial carcinoma: A multicenter propensity score‐matched cohort study comparing a period before the introduction of pembrolizumab (2003–2011) and a more recent period (2016–2020)
por: Taguchi, Satoru, et al.
Publicado: (2022) -
Quantification of the individual risk of each Gleason pattern, including tertiary Gleason pattern 5, after radical prostatectomy: development of the modified Gleason grade grouping (mGGG) model
por: Taguchi, Satoru, et al.
Publicado: (2020) -
Clinical characteristics of patients with inguinal hernia mesh migration into the bladder
por: Akimoto, Takahiro, et al.
Publicado: (2022) -
Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma
por: Teshima, Taro, et al.
Publicado: (2022)